PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Fexofenadine hydrochloride - Allergic rhinitis

PAD Profile : Fexofenadine hydrochloride - Allergic rhinitis

Keywords :
Hay fever, hayfever, antihistamines, allergy, seasonal allergic rhinitis, pollen allergy, non-sedating antihistamines
Brand Names Include :
Telfast

Traffic Light Status

Status 1 of 1.

Status :
Green (see narrative)
Important
Formulations :
  • Tablets
Important Information :
2nd line to loratadine / cetirizine tablets. 120mg tablets available to buy over the counter.180mg tablets NOT licensed for allergic rhinitis. 30mg reserved for paediatrics.
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Guidelines

The following guidelines are available for this indication.

Other Drugs

Other Indications

No indications returned.

Additional Documents

Type
Document
Review Date
Guidelines (Local)
01 January 2024

Committee Recommendations

Date
Committee Name
Narrative
05 April 2023
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

Fexofenadine is recommended as a 2nd line treatment option.

Prescribe generically

NOTE - the 180mg tablets are NOT licensed for allergic rhinitis

Associated BNF Codes

03. Respiratory System
03.04.01. Antihistamines
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More